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Background: In areas co-endemic for multiple Plasmodium species, correct diagnosis is crucial for appropriate
treatment and surveillance. Species misidentification by microscopy has been reported in areas co-endemic for
vivax and falciparum malaria, and may be more frequent in regions where Plasmodium knowlesi also commonly
occurs.
Methods: This prospective study in Sabah, Malaysia, evaluated the accuracy of routine district and referral
hospital-based microscopy, and microscopy performed by an experienced research microscopist, for the diagnosis
of PCR-confirmed Plasmodium falciparum, P. knowlesi, and Plasmodium vivax malaria.
Results: A total of 304 patients with PCR-confirmed Plasmodium infection were enrolled, including 130 with P.
knowlesi, 122 with P. falciparum, 43 with P. vivax, one with Plasmodium malariae and eight with mixed species
infections. Among patients with P. knowlesi mono-infection, routine and cross-check microscopy both identified 94
(72%) patients as “P. malariae/P. knowlesi”; 17 (13%) and 28 (22%) respectively were identified as P. falciparum, and
13 (10%) and two (1.5%) as P. vivax. Among patients with PCR-confirmed P. falciparum, routine and cross-check
microscopy identified 110/122 (90%) and 112/118 (95%) patients respectively as P. falciparum, and 8/122 (6.6%) and
5/118 (4.2%) as “P. malariae/P. knowlesi”. Among those with P. vivax, 23/43 (53%) and 34/40 (85%) were correctly
diagnosed by routine and cross-check microscopy respectively, while 13/43 (30%) and 3/40 (7.5%) patients were
diagnosed as “P. malariae/P. knowlesi”. Four of 13 patients with PCR-confirmed P. vivax and misdiagnosed by routine
microscopy as “P. malariae/P. knowlesi” were subsequently re-admitted with P. vivax malaria.
Conclusions: Microscopy does not reliably distinguish between P. falciparum, P. vivax and P. knowlesi in a region
where all three species frequently occur. Misdiagnosis of P. knowlesi as both P. vivax and P. falciparum, and vice
versa, is common, potentially leading to inappropriate treatment, including chloroquine therapy for P. falciparum
and a lack of anti-relapse therapy for P. vivax. The limitations of microscopy in P. knowlesi-endemic areas supports
the use of unified blood-stage treatment strategies for all Plasmodium species, the development of accurate rapid
diagnostic tests suitable for all species, and the use of PCR-confirmation for accurate surveillance.
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Despite recent progress towards elimination, malaria con-
tinues to affect over 200 million people per year with an
estimated 655,000 deaths [1]. Although most deaths are
caused by Plasmodium falciparum, the relative contribu-
tion of the non-falciparum Plasmodium species to the
global malaria burden is increasing as incidence of P.
falciparum falls [2-4]. The most widely distributed of these
species is Plasmodium vivax, which accounts for half of
the world’s malaria and is increasingly recognized as a
cause of severe and potentially fatal disease [5-8]. More-
over, reducing transmission of P. vivax has proved more
difficult than P. falciparum, with successful malaria con-
trol programmes in some countries leading to an increase
in incidence of P. vivax as overall malaria rates drop [2,3].
More recently, the simian parasite Plasmodium knowlesi
has been identified as the most common cause of human
malaria in parts of Malaysia [9-14], with its emergence
also associated with reduction in incidence of the human
Plasmodium species [12]. Plasmodium knowlesi is capable
of causing severe disease and death [9,13,15-18], and is
increasingly reported in other Southeast Asian countries
[19].
In areas co-endemic for P. falciparum, P. vivax and P.
knowlesi, species-differentiation at the time of diagnosis
is crucial for directing appropriate treatment, particu-
larly in settings which have separate treatment policies
for different species, most commonly artemisinin-
combination treatment (ACT) for P. falciparum and
chloroquine for non-falciparum species. Even in regions
such as Papua, Indonesia, which have adopted a unified
treatment strategy of ACT for all malaria [1], diagnosis
of P. vivax is still required to allow administration of
anti-hypnozoite treatment to prevent relapses, with mis-
diagnosis of this species potentially leading to increased
morbidity and transmission. In areas also endemic for P.
knowlesi, accurate diagnosis is important for epidemio-
logical surveillance of this potentially fatal emerging zoo-
notic infection.
Microscopy of stained blood smears remains the stan-
dard method of malaria diagnosis in most parts of the
malaria-endemic world, and ideally allows differentiation
of species. However, with the difficulty in distinguishing
young ring-stage parasites, frequent misdiagnosis has been
reported in areas co-endemic for P. falciparum and P.
vivax [20,21]. It is well established that microscopy cannot
reliably distinguish P. knowlesi from Plasmodium mala-
riae [22,23], but misdiagnosis of P. knowlesi with other
species may also be frequent [13]. This study therefore
evaluated the accuracy of both routine hospital micros-
copy and microscopy performed by an experienced re-
search microscopist, for the diagnosis of P. falciparum, P.
knowlesi, and P. vivax, in an area where all three species
commonly occur.Methods
Study site and referral system
The study was conducted at Queen Elizabeth Hospital
(QEH), an adult tertiary referral hospital in Kota Kinabalu,
Sabah, Malaysia. The hospital services the West Coast and
Kudat Divisions of Sabah, with six district hospitals and a
population of 1.14 million. From September 2010, in re-
sponse to ongoing malaria deaths in Sabah [16], new treat-
ment and referral guidelines were instituted and included
tertiary hospital referral for all malaria patients with a
thick blood film reported as “4+” (indicating >10 para-
sites/high-power microscopy field [24]) or who had any
evidence of severe malaria. Treatment was commenced
prior to transfer and a pre-treatment blood film was sent
with the patient. Local health clinics within the Kota
Kinabalu area were required to refer all malaria patients to
QEH for admission, with treatment commenced on
arrival.
Subjects
All patients referred to or admitted directly to QEH with a
microscopic diagnosis of malaria were assessed for eligibil-
ity from September 2010 to October 2011 as part of a pro-
spective study of the epidemiology, clinical spectrum and
pathophysiology of knowlesi malaria, reported elsewhere
[15]. Non-pregnant patients ≥12 years old were enrolled if
they were within 18 hours of commencing malaria treat-
ment, had no major co-morbidities, and had not already
been enrolled in the study. Patients who were PCR nega-
tive were retrospectively excluded. Patients were classified
as having severe malaria using modified 2010 WHO
Severe Malaria Criteria [15,25,26]. Written informed con-
sent was provided by patients or their relatives. Ethics
approval was obtained from the Medical Research Sub-
Committee of the Malaysian Ministry of Health and the
Health Research Ethics Committee of the Menzies School
of Health Research, Australia.
Study procedures
Standardized data forms were used to record demo-
graphic and clinical information. Venous blood was
collected in a CTAD tube labelled with the patient’s
study number, and thick and thin blood smears prepared
using Giemsa staining. Species identification using thick
and thin blood films was performed initially by micro-
scopists at referring district hospitals, or at QEH if pre-
senting directly to this hospital (routine microscopy).
Thick and thin films were later cross-checked by a re-
search microscopist (cross-check microscopy) with more
than 15 years’ experience, who was blinded to the results
of routine microscopy. Because reliable differentiation of
P. knowlesi from P. malariae is not possible [27], slides
reported as P. malariae, P. knowlesi, or P. malariae/P.
knowlesi were all considered a single group, further
Table 1 PCR results compared with routine microscopy
Microscopy PCR
Pf Pv Pk Pm Pf/Pv Pf/Pk Pf/Pm Total
Pf 110 3 17 0 2 2 0 134
Pv 1 23 13 0 1 0 0 38
"Pm/Pk" 8 13 94 1 0 0 1 117
"Pm/Pk"/Pv 0 3 2 0 0 1 0 6
"Pm/Pk"/Pf 2 0 3 0 0 0 0 5
Pf/Pv 1 1 0 0 1 0 0 2
“P species” 0 0 1 0 0 0 0 1
Total 122 43 130 1 4 3 1 304
Abbreviations: Pf = Plasmodium falciparum, Pv = Plasmodium vivax, Pk =
Plasmodium knowlesi, Pm = Plasmodium malariae, P = Plasmodium.
Table 2 PCR results compared with cross-check
microscopy
Microscopy PCR
Pf Pv Pk Pm Pf/Pv Pf/Pk Pf/Pm Total
Pf 112 0 28 0 1 3 0 144
Pv 1 34 2 0 1 0 0 38
"Pm/Pk" 5 3 94 1 0 0 1 104
Pf/Pv 0 1 2 0 1 0 0 4
Po 0 2 0 0 0 0 0 2
Negative 0 0 4* 0 0 0 0 4
Total 118 40 130 1 3 3 1 296
Abbreviations: Pf = Plasmodium falciparum, Pv = Plasmodium vivax, Pk =
Plasmodium knowlesi, Pm = Plasmodium malariae, Po = Plasmodium ovale.
Note: Slides were unavailable for cross-check microscopy for eight patients.
Cross-check microscopy was performed on pre-treatment slides for 280 (95%)
of 296 patients.
*Includes one post-treatment slide. Parasite counts (according to routine
microscopy results) of remaining three patients were 32, 55 and 1574
parasites/μL.
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was quantified by the research microscopist using pre-
treatment slides, and reported as the number of para-
sites per 200 white blood cells or per 1,000 red blood
cells and converted to parasites/μL using the patient’s
white blood cell count or haematocrit, respectively. If a
pre-treatment slide could not be reliably obtained (6% of
total slides) the referring hospital’s microscopy report
was used and the “1+ − 4+” grade converted into para-
sites/μL using the relevant median parasite density. Para-
site DNA was extracted and PCR performed using
previously described methods for P. falciparum, P. vivax,
Plasmodium ovale, and P. malariae [28] and P. knowlesi
[29]. PCR diagnosis was used as the gold standard.
Patients were followed-up on days 14 and 28 if possible,
and/or if readmitted to QEH.
Statistical analysis
Data were analysed using STATA version 10.1 (Stata-
Corp LP, College Station, TX, USA). For continuous
variables intergroup differences were compared using
the Kruskal-Wallis test, or the Mann–Whitney test for
pairwise comparisons, while the χ2 test was used for
intergroup differences between categorical variables. Lo-
gistic regression was used to assess the association
between parasite count and correct identification of
species.
Results
A total of 304 patients with PCR-confirmed Plasmodium
infection were enrolled, including 130 with P. knowlesi,
122 with P. falciparum, 43 with P. vivax, one with P.
malariae, and eight with mixed-species infection. Demo-
graphic and clinical features are reported separately [15].
Half (51%) of all patients were referred from district hos-
pitals, including 86 (66%) with knowlesi malaria, 47
(39%) with P. falciparum, and 21 (49%) with P. vivax
malaria. Severe malaria occurred in 38 (29%) patients
with P. knowlesi, 13 (11%) with P. falciparum, and seven
(16%) with P. vivax [15]. Patients with non-severe P.
knowlesi had lower parasite counts than those with non-
severe P. falciparum (4,837 [IQR 1576–14,641] vs 10,500
[IQR 4,014–32,267] parasites/μL, p < 0.01), but not P.
vivax (median 4,753 [IQR 2369–10,316] parasites/μL,
p = 0.95). Among patients with severe malaria, there was
no significant difference in median parasitaemia of
those with P. knowlesi (80,359 [IQR 25,857–168,279]
parasites/μL) and P. falciparum (72,270 [IQR 27,905–
273,909] parasites/μL, p = 0.78).
Microscopy and PCR results are shown in Tables 1 and
2. Slides were unavailable for cross-check microscopy for
eight (2.6%) patients. Routine and cross-check microscopy
correctly identified the species in 229/304 (75%) and
242/296 (82%) patients respectively (p = 0.055), with 188/296 (64%) patients correctly diagnosed by both micro-
scopic methods. Among patients with PCR-confirmed P.
knowlesi mono-infection, routine and cross-check micros-
copy each correctly identified 94 (72%) patients as “P.
malariae/P. knowlesi”, with 66 (51%) patients correctly
diagnosed by both microscopy readings. Routine micros-
copy diagnosed 17 (13%) and 13 (10%) patients with PCR-
confirmed P. knowlesi mono-infection as P. falciparum
and P. vivax respectively, while cross-check microscopy
diagnosed 28 (22%) and two (1.5%) as P. falciparum and
P. vivax respectively. Four (3%) patients with PCR-
confirmed P. knowlesi were diagnosed by both routine and
cross-check microscopy as P. falciparum, and no patient
was diagnosed by both readings as P. vivax. Among the 38
patients with severe knowlesi malaria, routine microscopy
correctly diagnosed 33 (87%) as “P. malariae/P. knowlesi”.
Three were diagnosed as P. falciparum, one as P. vivax
and one as P. falciparum/“P. malariae/P. knowlesi”. The
median parasite count among the five patients with severe
knowlesi malaria and misdiagnosed by routine microscopy
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was not significantly different to those correctly diagnosed.
Among patients with PCR-confirmed P. falciparum,
routine and cross-check microscopy correctly identified
110/122 (90%) and 112/118 (95%) as P. falciparum,
while 8/122 (6.6%) and 5/118 (4.2%) patients respectively
were diagnosed as “P. malariae/P. knowlesi”. All 13
patients with severe falciparum malaria were correctly
diagnosed by routine microscopy.
Among those with PCR-confirmed P. vivax, 23/43
(53%) and 34/40 (85%) were correctly diagnosed by
routine and cross-check microscopy respectively, while
13/43 (30%) and 3/40 (7.5%) patients were diagnosed as
“P. malariae/P. knowlesi”. Among the 13 patients with
PCR-confirmed P. vivax and misdiagnosed by routine
microscopy as “P. malariae/P. knowlesi”, four (31%) were
re-admitted to QEH within four months with PCR-
confirmed P. vivax infection. Among the seven patients
with severe vivax malaria, routine microscopy diagnosed
three as P. vivax, two as “P. malariae/P. knowlesi”, one
as P. falciparum/P. vivax, and one as “P. malariae/P.
knowlesi”/P. vivax.
Among the eight patients with mixed-species infection
by PCR, one patient with P. falciparum/P. vivax was
correctly identified by routine microscopy, and another
with P. falciparum/P. vivax was correctly identified by
cross-check microscopy. All others were misdiagnosed
by both microscopic readings (with one patient’s slide
unavailable for cross-check microscopy).
An association was found between parasite count and
correct identification of P. vivax by routine microscopy
(OR [log increase] 1.64 [95% CI 1.01 – 2.68], p = 0.046),
with a similar trend also seen with identification of P.
vivax by cross-check microscopy (OR [log increase] 1.73
[95% CI 0.96 – 3.10], p = 0.067). No association however
occurred between parasite count and correct identifica-
tion of P. knowlesi or P. falciparum, by either routine or
cross-check microscopy.
Discussion
This study highlights the difficulties of microscopic diag-
nosis of Plasmodium species in an area where P. falcip-
arum, P. vivax and P. knowlesi all commonly occur.
Misdiagnosis of P. knowlesi as both P. vivax and P.
falciparum, and vice versa, is common. Only 72% of
patients with PCR-confirmed P. knowlesi received an
accurate diagnosis by routine or by cross-check micros-
copy, and correlation between the microscopic methods
was poor, with even fewer patients receiving an accurate
diagnosis of P. knowlesi by both methods. These findings
occurred despite considering P. knowlesi and P. malariae
as a single group, and so were not a consequence of the
well described near impossibility of distinguishing these
two species. Rather, patients with PCR-confirmed P.knowlesi were commonly misdiagnosed as having either
P. falciparum or P. vivax malaria, with misdiagnosis of
P. vivax as “P. malariae/P. knowlesi” also common.
The difficulty with distinguishing P. knowlesi from P.
falciparum by microscopy has been previously described,
due to similarities between the young rings of P. knowlesi
and ring forms of P. falciparum, including double chroma-
tin dots, multiple-infected erythrocytes and applique
forms [22,23]. In a previous study in Sarawak, 11/216 (5%)
patients diagnosed by microscopy as “P. malariae” were
actually P. falciparum by PCR, and 33/312 (11%)
microscopy-diagnosed P. falciparum cases were P. know-
lesi by PCR [13]. In this previous study and in the current
study, however, the difficulty differentiating P. knowlesi
and P. vivax was also notable. In the current study 30% of
patients with PCR-confirmed P. vivax were misdiagnosed
by routine microscopy as “P. malariae/P. knowlesi”, with
four patients subsequently re-admitted with presumed
vivax relapses due to lack of primaquine treatment. In the
Sarawak study, 43 of 440 (10%) patients with PCR-
confirmed P. vivax malaria were misdiagnosed as “P.
malariae” [13]. In a series of malaria deaths in Sabah, one
of six fatal cases of P. knowlesi was misdiagnosed as P.
vivax by microscopy and a fatal case of P. vivax was mis-
diagnosed as “P. malariae” [18].
This frequent misdiagnosis of P. vivax as “P. malariae/
P. knowlesi” has significant implications for malaria con-
trol, as failure to administer anti-hypnozoite treatment
may lead to increased transmission and may hamper
efforts to eliminate vivax malaria in regions where P.
knowlesi is common. These findings support the current
Sabah Ministry of Health policy for the performance of
reference centre PCR on all patients with a microscopic
diagnosis of “P. malariae/P. knowlesi” to enable adminis-
tration of primaquine to those found to have misdiag-
nosed P. vivax. In knowlesi-endemic areas, where
logistically possible, PCR should also be performed on at
least a proportion of slides diagnosed as P. falciparum
or P. vivax, to allow monitoring of the accuracy of
microscopic diagnoses at different clinical sites, and to
identify areas where additional training of microscopists
may be required. Given the inaccuracies of microscopic
diagnosis, performance of PCR is also essential to main-
tain accurate surveillance, particularly monitoring the
emergence of P. knowlesi.
The inaccuracy of microscopy for differentiating
Plasmodium species creates difficulties with basing
treatment decisions on microscopic results. The 2008
Malaysian Ministry of Health malaria treatment guide-
lines recommend chloroquine for uncomplicated P.
malariae/P. knowlesi malaria; chloroquine plus prima-
quine for uncomplicated P. vivax malaria; artemisinin
combination treatment (ACT; artesunate/mefloquine
[ArtequineW] or artemether/lumefantrine [RiametW]) for
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artesunate, or intravenous quinine plus oral doxycycline,
for severe P. falciparum or severe P. malariae/P. knowlesi
malaria [30]. No recommendations are given for treat-
ment of severe vivax malaria. At Queen Elizabeth Hos-
pital and referral hospitals in its catchment area, updated
treatment guidelines recommend ACT for uncomplicated
P. falciparum or P. malariae/P. knowlesi malaria; chloro-
quine plus primaquine, or ACT, for uncomplicated P. vivax
malaria; and intravenous artesunate (followed by oral the-
rapy as above) for severe malaria from any species [15].
Given the different treatment recommendations for
each species in both of these guidelines, inappropriate
treatment decisions may be made as a result of incorrect
microscopic diagnoses. Misdiagnosis of P. falciparum as
P. knowlesi would, under current national guidelines,
result in administration of chloroquine for P. falciparum.
Given widespread resistance of P. falciparum to chloro-
quine, this would lead to increased risk of complications
and/or fatal outcome, as well as increased transmission.
Patients with severe P. knowlesi malaria misdiagnosed as
P. vivax may fail to receive immediate parenteral treat-
ment if national guidelines are followed, and this sce-
nario has been previously associated with fatal outcomes
[18]. Even if the updated hospital guidelines are fol-
lowed, misdiagnosis of severe P. knowlesi as P. vivax
may still lead to treatment with oral chloroquine if signs
of severity are missed, potentially leading to adverse out-
comes given the slower parasite clearance associated
with chloroquine as compared to oral ACT [16].
These results therefore support the argument for a uni-
fied treatment strategy of ACT for uncomplicated malaria
from all Plasmodium species in knowlesi-endemic areas,
an approach increasingly recommended for regions co-
endemic for P. falciparum and P. vivax [31]. These data
also support the 2012 WHO recommendation for intra-
venous artesunate to be given to any patient meeting se-
vere malaria criteria [25]. Even if signs of severity are
overlooked among patients with knowlesi malaria, treat-
ment with oral ACT may ensure more rapid parasite
clearance and may lead to improved outcomes compared
to treatment with oral chloroquine [16], although the opti-
mal oral agent for uncomplicated P.knowlesi remains
undetermined.
An additional advantage of this unified treatment
approach would be the avoidance of inadvertent use of
chloroquine for P. falciparum misdiagnosed as another
species. Furthermore, chloroquine-resistant P. vivax is
an increasing problem throughout Southeast Asia [31],
and has been previously documented in Sabah [32]
and Peninsular Malaysia [33-35]. Use of chloroquine
for P. vivax malaria may therefore be associated with
treatment failures, and may potentiate spread of chloro-
quine resistance.Finally, this study highlights the need to develop rapid
diagnostic tests (RDTs) that have the ability to distin-
guish between Plasmodium species, in order that reliable
results can be obtained more quickly and cheaply than is
possible with PCR. Although histidine-rich protein 2
(HRP2)-based RDTs are able to diagnose P. falciparum,
RDTs that distinguish P. knowlesi from P. vivax are not
yet available. Limited data suggest that P. knowlesi cross-
reacts with both P. falciparum and P. vivax-specific
pLDH [36-39], and RDTs that combine these antigens
with HRP2 may therefore allow differentiation between
P. vivax, P. falciparum and P. knowlesi mono-infections.
However, while a pLDH RDT has shown high sensitivity
for the diagnosis of severe malaria from all three of these
species, neither pLDH- or aldolase-based RDTs have
demonstrated sufficiently high sensitivity for uncompli-
cated P. knowlesi [40]. Prospective evaluation of more
sensitive RDTs in knowlesi-endemic areas is needed.
This study has found that microscopy does not reliably
distinguish between P. falciparum, P. vivax and P. knowlesi
in areas co-endemic for all three species, with misdiag-
nosis of P. vivax and P. knowlesi particularly common.
In P. knowlesi-endemic areas these limitations of micro-
scopic diagnosis must be considered when developing
strategies to monitor the prevalence of the different mal-
aria species, and when developing treatment guidelines.
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